HIV-1 reverse transcriptase (RT) has a complex structure and encodes 560 amino acids in its N-terminal and C-terminal.1,2 Inhibitors of RT are widely used as antiretroviral agents globally. Mutations in the N-terminal are well-characterized precursors of resistance to RT inhibitors.3 Less is known about the C-terminal because standard genotyping focuses on the approximately 300 codons in the N-terminal. The connection domain (CD), codons 316–437, is the proximal part of the C-terminal and links the N-terminal to the RNaseH domain. It seems that CD mutations can evolve during antiretroviral therapy (ART) or contribute to resistance to specific RT inhibitors, but this is controversial and there is no consensus that CD mutations have clinical relevance.4–11 Of note, studies to date, with few exceptions,10 have focused on subtype B HIV-1. We determined the prevalence of CD mutations in ART-experienced HIV-1 patients infected with non–B subtype HIV-1 and investigated associations between CD mutations, N-terminal mutations, and resistance to RT inhibitors.
Participants were recruited between August 2009 and February 2010 from 4 outpatient HIV clinics in Mali, West Africa. Inclusion criteria were as follows: confirmed HIV-1 infection and virologic failure on nevirapine (NVP)-based first-line therapy or boosted protease inhibitor (PI)–based second-line therapy. Virologic failure was defined as plasma HIV-1 RNA >1000 copies per milliliter after at least 6 months on current regimen. Patients with HIV-2 co-infection were excluded. The ethics committee of the University of Bamako School of Medicine approved the study. Each patient gave informed consent.
Procedures and Definitions
CD4+ T-cell (CD4) count and HIV RNA measurement were performed at the Virology Laboratory, University of Bamako, using the BD FACSCount (Becton, Dickinson and Company, San Jose, CA) and Easy Q HIV-1 v1.2 assay (EQ; BioMerieux, France), respectively.
Full-length population sequencing (RT and Protease genes) and phenotyping were performed at Janssen Diagnostics, Beerse, Belgium, using frozen plasma samples. To create amplicons, RNA was extracted from plasma on an automated RNA extraction platform. The Gag (p7/p1-p1/p6) protease–reverse transcriptase coding sequence was reverse transcribed and amplified in a 1-step RT-polymerase chain reaction, followed by a nested polymerase chain reaction. For genotypic testing, Dideoxy sequencing reactions were performed on the purified amplicon. Sequence data files were grouped per sample identifier and aligned against the reference HXB2 reference sequence. Procedures used to determine viral phenotype are described in detail elsewhere.12 Phenotype was expressed as half maximal effective concentration (EC50) values defined as the concentration of compound achieving 50% inhibition of the virus-induced enhanced green fluorescent protein signals as compared with the untreated virus-infected control cells. The ratio between the plasma isolate EC50 and the wild-type reference virus (IIIB) EC50 gave the fold change value. Clade was determined using the vircoTYPE algorithm.
Drug resistance mutations in RT were interpreted according to the International AIDS Society–USA Drug Resistance Mutations 2011 update.3 Thymidine analogue mutations (TAMs) were defined as M41L, D67N, K70R, L210W, T215F/Y, K219E/Q. The CD mutations considered were E312Q, Y318F, G333D/E, G335C/D, N348I, A360I, A360V, V365I, A371V, A376S, and E399G.4
HIV-1 subtype was dichotomized as CRF02_AG (the predominant subtype in Mali) versus “other”. Mutations detected by genotype were included in analyses only if >10% prevalent in the study cohort. HIV phenotype for each drug was classified as resistant or sensitive based on EC50-fold change from wild-type virus inhibition. HIV RNA and CD4 counts were log-transformed to fit a uniform distribution. Multivariate models were chosen by step-wise removal of nonsignificant terms until the difference in the modified Bayesian information criterion suggested weak support for a nested model. The conservative Bonferroni correction offset the problem of multiple comparisons.
Three logistic regression analyses were performed to determine variables associated with the following: CD mutations; N-terminal mutations; and phenotypic drug resistance. Independent variables assessed in both univariate and multivariate analyses were CD4 count, HIV RNA, first-line failure, subtype CRF02_AG, and presence of G335D, A371V or “other CD” mutation. Multicollinearity of the independent variables was assessed by pair-wise correlations and found to be minimal with a mean variance inflation factor of 1.33. The P value threshold for significance was 0.05, uncorrected. Database management and analytical testing was completed on Stata SE 10.1 (College Station, TX).
Ninety-six individuals (76 failing first-line ART and 20 failing second-line ART) met inclusion criteria. The first-line regimen for all 96 individuals was NVP plus lamivudine (3TC) plus a thymidine analogue [zidovudine (ZDV) or stavudine]. Second-line therapy comprised a ritonavir-boosted PI and 2 or 3 nucleos(t)ide reverse transcriptase inhibitors (NRTI). The specific antiretroviral drugs used in second line were ritonavir-boosted lopinavir (90%), 3TC (75%), ZDV (40%), didanosine (30%), abacavir (30%), tenofovir (20%), and stavudine (10%). HIV-1 subtypes were CRF02_AG (69.8%), CRF06_cpx (16.7%), CRF09_cpx (4.2%), and other (any of subtype C, subtype A1, CRF01_AE, CRF19_cpx, subtype G, CRF05_DF = 9.4%). Median (IQR) CD4 count was similar in both failure groups [137.5 (93.0-255.5) versus 143.5 (110.5-222.5) cells/mm3, P = 0.675]. Median (IQR) HIV RNA was higher in the second-line failure group [log10 4.29 (3.83–4.82) versus log10 5.28 (4.75–5.74) copies/mL, P < 0.005].
Distribution of CD and N-Terminal Mutations
Table 1 shows prevalence of CD mutations, N-terminal mutations, resistant phenotypes, and their associations in univarate analysis. Eight CD mutations were identified as follows: G335D (82.3%), A371V (69.8%), E399D (9.4%), N348I (5.2%), V365I (4.2), 318F (2.1%), G333E (2.1%), and A360V (2.1%). In univariate analysis, G335D [odds ratio (OR) 19.9 (95% confidence interval: 5.1 to 78.2), P < 0.005] and A371V [OR: 10.8 (3.9 to 30.0), P < 0.005] were significantly associated with CRF02_AG, and with each other [OR 8.75 (2.7 to 28.3), P < 0.005]. After controlling for HIV-1 subtype, their association with each other diminished [OR: 3.16 (0.8 to 12.4), P = 0.10], thus highlighting separate independent associations of G335D and A371V with viral subtype [G335D OR: 12.0 (2.8 to 52.6), P < 0.005; A371V OR 7.0 (2.3 to 21.7), P < 0.005]. CD4 count, HIV RNA, or treatment failure group did not affect the prevalence of CD mutations.
The most prevalent N-terminal mutations were M184V/I (55.2%), Y181C/I/V (29.2%), K103N (20.8%), and TAMs (19.8%). Forty-seven other mutations were present, each in less than 10% of the cohort. There were no differences in the prevalence of the N-terminal mutations by CD4 count or HIV RNA. On univariate analysis, M184V/I was associated with “other” CD mutations [OR: 2.91 (1.03 to 8.2), P = 0.043]. The association remained significant in a multivariate model [OR 4.1 (1.3 to 12.5), P = 0.014, Bonferroni adjusted significance = 0.025]. Within the examined cohort, K103N mutation was only present in subtype CRF02_AG (P < 0.005) and always occurred with G335D (P = 0.019). In analysis limited to only CRF02_AG (n = 67), there was no longer an association between K103N and G335D (P = 0.549, Fisher' exact). G190A (10.4% prevalence) was negatively associated with CRF02_AG [OR: 0.14 (0.02 to 0.8), P = 0.028] amongst first-line failures (n = 76) in multivariate modeling.
Phenotypic Resistance to RT Inhibitors
Among patients who completed phenotypic resistance testing (n = 69), resistance irrespective of treatment experience was most prevalent against NVP (69.6%), 3TC (66.7%), efavirenz (62.3%), and emtricitabine (62.3%). In the multivariate model, NVP resistance was less likely with subtype CRF02_AG [OR: 0.17 (0.03 to 0.90), P = 0.037] despite 100% prevalence of K103N within CRF02_AG virus. The only other prevalent NVP-specific resistance mutations were Y181C/I/V (29.0%) and G190A (7.3%), and they were always associated with phenotypic NVP resistance. However, K103N, Y181C/I/V mutations and G190A were not collinear and were absent in 27.1% of isolates with phenotypic NVP resistance. Further univariate analysis dichotomizing subtype as CRF02_AG (n = 50) versus CRF06_CPX (n = 12) attenuated the association of CRF02_AG with reduced likelihood of phenotypic resistance to NVP [OR: 0.12 (0.02 to 1.24), P = 0.078], but remained significant after controlling for A371V [OR 0.50 (0.003 to 0.66), P = 0.023]. Phenotypic etravirine resistance was present in 37.7% of isolates with no difference between first-line and second-line failure groups [OR: 4.3 (0.8 to 22.7), P = 0.091] on multivariate analysis.
On univariate analysis, G335D was associated with reduced risk of resistance to NVP [OR: 0.12 (0.01 to 0.99), P = 0.049] and etravirine [OR: 0.31 (0.09 to 1.00), P = 0.05], but not efavirenz [OR: 0.34 (0.09 to 1.3), P = 0.121]. In the multivariate model, there remained a significant association with reduced risk of resistance to etravirine [OR: 0.27 (0.08 to 0.94), P = 0.040] in the presence of G335D. The reduction of resistance to etravirine is further highlighted when controlling for Y181C/V/I mutations and presence of K103N [OR: 0.10 (0.02 to 0.7), P = 0.020]. For NVP, the protective effect of G335D was also evident (OR: 0.09, P = 0.034), however, it was difficult to separate the effect of subtype. The protection remained significant in those without K103N or Y181C/V/I mutations [OR: 0.04 (0.005 to 0.4), P = 0.008, n = 37].
We identified 8 CD mutations, most commonly G335D (82.3%) and A371V (69.8%), among HIV-1 patients failing ART in Mali. Each of the other identified CD mutations (E399D, N348I, V365I, 318F, G333E, and A360V) was less than 10% prevalent. The distribution of CD mutations was similar in first-line and second-line failures. In addition, the distributions of HIV-1 subtypes and CD mutations in the 2 failure groups in our study were similar to data from ART-naive patients in Mali.13 These findings suggest that the CD mutations are largely polymorphic in the study population. A high prevalence of CD mutations has been reported as well in CRF01_AE-infected patients experiencing treatment failure.10 In B subtype HIV-1, CD mutations are less common and seem to evolve during ART. This was demonstrated in the OPTIMA study (96.8% subtype B) where the frequencies of CD mutations in ART failures were A371V (21.4%), A376S (15.5%), and N348I (12.9%).4 CD mutations in OPTIMA were less frequent than observed in our study, but more frequent than in treatment-naive subtype B patients. In another study, N3481, R356K, R358K, A360V, and A371V were more frequently detected in ART-exposed compared with ART-naive subtype B patients.5
It is uncertain whether CD mutations have clinical relevance, despite suggestions that some can influence antiretroviral susceptibility, typically when co-existent with N-terminal mutations. Illustratively, polymorphic G335D or A371V in CRF01_AE subtype did not confer resistance by themselves, but there was increased ZDV resistance when either of these mutations was present with TAMs.10 In subtype B, CD mutations that have been associated with resistance include E312Q, G333E/D, G335D, N3481, A360I/V, V365I, T369I, A371V, and A376S,6–9 but these associations are controversial; other investigators did not find a major detrimental effect of N3481, R356K, R358K, A360V, or A371V on response to ART.5 In the current study, we found an association between presence of G335D and a tendency toward reduced risk of phenotypic etravirine or NVP resistance. No association was detected between resistance to any NRTI and detection of CD mutation(s). Our finding should be interpreted with caution because we could not completely untangle potential confounding effects of viral subtype. Further, K103N was seen primarily in CRF02_AG subtype and always with G335D in our cohort. The K103N mutation does not cause etravirine resistance and it has been suggested that it may increase susceptibility to etravirine.14 In contrast to our results from a non–B subtype HIV population, a previous study found that CD mutations had no impact on virologic response to etravirine, but approximately two-thirds of the patients in that study had B subtype HIV infection.15 Also in contrast to our results, studies with approximately 90% B subtype HIV-1 representation reported that N348I and A376S conferred varying degrees of NVP resistance11 and that E399D conferred resistance to etravirine.16
A key strength of our study is that we assessed phenotypic resistance, thus avoided potential flaws of genotype-based resistance algorithms especially with poorly characterized CD mutations. Because we did not have pretreatment and longitudinal samples from the patients however, we were unable to ascertain which CD mutations were present before ART exposure. Nevertheless, comparison of our result with data from treatment-naive patients revealed striking similarities in the distribution of CD mutations, suggesting that selection of CD mutations under antiretroviral drug pressure was uncommon in our cohort. “Phylogenetic analysis suggested rare transmission events and did not alter our results (data not shown)”.
In conclusion, there is a high prevalence of CD mutations in non–B subtype HIV-1 patients failing ART in Mali. Identified CD mutations are likely polymorphic and do not seem to confer NRTI or nonnucleos(t)ide reverse transcriptase inhibitor resistance in the prevalent subtypes. Our finding of a tendency toward reduced resistance to etravirine and NVP in the presence of G335D should be investigated further.
The authors thank Mr Issiaka Sogodogo (Mali) for his assistance with sample collection and Mr Kevin Kunstman (Northwestern University) for technical assistance with resistance testing. The authors also like to acknowledge the contribution of Janssen Diagnostics BVBA, Belgium to this work. Finally, the authors thank all the patients who participated in the study.
1. Jacobo-Molina A, Ding J, Nanni RG, et al.. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993;90:6320–6324.
2. Kohlstead LA, Wang J, Friedman JM, et al.. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–1790.
3. Johnson VA, Calvez V, Günthard HF, et al.. 2011 Update of the drug resistance
mutations in HIV-1. Top Antivir Med. 2011;9:156–164.
4. Dao B, Ayers D, Singer J, et al.. Connection domain
mutations in treatment-experienced
patients in the OPTIMA Trial. J Acquir Immune Defic Syndr. 2010;54:160–166.
5. Von Wyl V, Ehteshami M, Demeter LM, et al.. HIV-1 reverse transcriptase connection domain
mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis. 2010;51:620–628.
6. Brehm JH, Koontz D, Meteer JD, et al.. Selection of mutations in the connection and Rnase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance
to 3'-azido-3'-dideoxythymidine. J Virol. 2007;81:7852–7859.
7. Nikoenko GN, Delviks-Franenberry KA, Palmer S, et al.. Mutations in the connection domain
of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance
. Proc Natl Acad Sci USA. 2007;2:317–322.
8. Zelina S, Sheen CW, Radzio J, et al.. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance
to zidovudine and lamivudine. Antimicrob Agents Chemother. 2008;52:157–163.
9. Yap SH, Sheen CW, Fahey J, et al.. N348I in the connection domain
of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
. PloS Med. 2007;4:e335.
10. Tanuma J, Hachiya A, Ishigaki K, et al.. Impact of CRF01_AE specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodfeiciency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect. 2010;12:1170–1177.
11. Hachiya A, Shimane K, Sarafinos S, et al.. Clinical relevance of substitutions in the connection subdomain and RNaseH domain of HIV-1 reverse transcriptase from a cohort of antiretrocviral treatment-naive patients. Antiviral Res. 2009;82:115–1121.
12. Pattery T, Verlinden Y, De Wolf H, et al.. Development and performance of conventional HIV-1 phenotyping (Antivirogram®
) and genotype-based calculated phenotyping assay (virco®
TYPE HIV-1) on Protease and Reverse Transcriptase genes to evaluate drug resistance
. Intervirology. 2012;55:138–146.
13. Haidara A, Chamberland A, Sylla M, et al.. High level of primary drug resistance
. HIV Med. 2010;11:404–411.
14. Marcelin AG, Flandre P, Descamps D, et al.. Factors associated with virological response to etravirine
in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother. 2010;54:72–77.
15. Gupta S, Vingerhoets J, Fransen S, et al.. Connection domain
mutations in HIV-1 reverse transcriptase do not impact etravirine
susceptibility and virologic responses to etravirine
-containing regimens. Antimicrob Agents Chemother. 2011;55:2872–2879.
16. Poveda E, de Mendoza C, Pattery T, et al.. Phenotypic impact of resistance
mutations on etravirine
susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS. 2008;22:2395–2398.